TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline

China‑based TJ Biopharma announced today the successful completion of a Series C2 financing round that raised nearly RMB 600 million (≈ US $84 million). The deal was led by a fund under CICC Capital and included participation from Yijing Capital and a host of other institutional investors. Existing shareholders – Heda Capital and Tsing Song Capital – also increased their stakes, underscoring confidence in the company’s growth trajectory.

Purpose of the Capital Injection

The fresh capital will be deployed primarily to:

1. Advance Phase 3 clinical trials and regulatory submissions for TJ Biopharma’s two flagship candidates, the CD38 antibody Felzartamab and the long‑acting growth‑hormone analogue Eftansomatropin Alfa.
2. Accelerate development of its second‑tier pipeline of globally innovative drug candidates, leveraging the company’s proprietary IG Plus integrated technology platform.

Portfolio Highlights

• Felzartamab (CD38 antibody) – a next‑generation therapeutic for multiple myeloma and other plasma‑cell disorders.
• Eftansomatropin Alfa – a long‑acting growth‑hormone analogue poised for approval in growth‑hormone deficiency.
• Efmedaglutide Alfa (TJ103/TG103) – a long‑acting GLP‑1 fusion protein developed in partnership with CSPC Pharma.
• Uliledlimab (CD73 antibody) – a novel immunotherapeutic in collaboration with Sanofi, currently in clinical trials.
• Plonmarlimab – targeting macrophage‑activation syndrome (MAS) and gouty arthritis.
• Givastomig (CLDN18.2 × 4‑1BB bispecific antibody) – the first‑in‑class bispecific designed to engage tumor‑associated antigens and costimulatory signals.

Technology & Partnerships

TJ Biopharma’s IG Plus platform integrates conditional 4‑1BB bispecific antibodies and masked peptide prodrugs, providing a modular, scalable approach to drug discovery. The company’s multi‑tiered pipeline spans autoimmune diseases, immuno‑oncology, and metabolic disorders, positioning it at the forefront of next‑generation therapeutics.

Market Outlook

With a robust pipeline and a growing portfolio of partnerships, TJ Biopharma is poised to capture a sizeable share of the rapidly expanding immuno‑oncology and metabolic‑disorder markets. The Series C2 financing strengthens the company’s ability to bring its lead candidates to market, while the second‑tier platform accelerates the development of future‑generation biologics.-Fineline Info & Tech